相关实验视频
Updated: Jul 1, 2025
08:51
A New Murine Model of Endovascular Aortic Aneurysm Repair
Published on: July 7, 2013
14.4K
血管内皮生长因子抑制剂和大动脉动脉瘤和大动脉解剖的风险
Chia-Wei Wu1, Hsin-Yi Huang2, Shin-Yi Lin1,2
1Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.
JAMA network open
|March 4, 2024
概括
血管内皮生长因子通路抑制剂 (VPIs) 与癌症患者中大动脉动脉瘤和剖析风险的增加有关. 这种风险特别与大动脉剖析有关,尤其是长时间的VPI暴露.
科学领域:
- 在瘤学瘤学.
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管内皮生长因子通路抑制剂 (VPIs) 用于癌症治疗.
- 静脉血管感染与潜在的血管并发症有关,包括大动脉动脉瘤 (AA) 和大动脉剖析 (AD).
研究的目的:
- 调查VPI使用与癌症患者发展AA和AD的风险之间的关联.
- 量化与特定VPI (sorafenib,sunitinib,pazopanib) 相关的AA和AD风险.
主要方法:
- 一项基于人口的,嵌套的病例控制研究,使用2011-2019年台湾国家索赔数据.
- 包括20岁以上患有脏,肝脏,胃肠道或胰腺癌的患者.
- 匹配的病例 (AA/AD诊断) 与基于年龄,性别,癌症类型和队列进入日期的对照.
主要成果:
- 总共分析了1461个病例和7198个对照.
- 在事件发生前100天内,VPI暴露与AA/AD风险增加有关 (aOR,2.10).
- 风险主要是由VPI相关的大动脉剖析 (aOR,3.09) 驱动的,持续时间较长和累计VPI剂量较高进一步增加了风险.
结论:
- 索拉费尼布,苏尼尼布和帕佐帕尼布的使用与癌症患者的AA和AD风险增加有关.
- 增加的风险主要与大动脉剖析有关.
- 需要进一步的研究来确定特定的风险因素,并确认与VPI相关的AA/AD的类效应.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
01:10Mechanism of Angiogenesis
5.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K